Volume 23 Issue 2
Feb.  2025
Turn off MathJax
Article Contents
Article Navigation >  Chinese Journal of General Practice  > 2025  >  23(2): 231-234
ZHANG Yuting, SHEN Wei, GU Jiaping. The correlation between IL-33, TIMP-1, MMP-2 and prognosis of chronic hepatitis B cirrhosis[J]. Chinese Journal of General Practice, 2025, 23(2): 231-234. doi: 10.16766/j.cnki.issn.1674-4152.003874
Citation: ZHANG Yuting, SHEN Wei, GU Jiaping. The correlation between IL-33, TIMP-1, MMP-2 and prognosis of chronic hepatitis B cirrhosis[J]. Chinese Journal of General Practice, 2025, 23(2): 231-234. doi: 10.16766/j.cnki.issn.1674-4152.003874
shu

The correlation between IL-33, TIMP-1, MMP-2 and prognosis of chronic hepatitis B cirrhosis

doi: 10.16766/j.cnki.issn.1674-4152.003874

  • Department of Infectious, Linping Campus, the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 311100, China

Funds:

 2024KY1462

  • Received Date: 2024-03-31
    Available Online: 2025-03-27
    Abstract
  •   Objective  To investigate the changes of serum interleukin-33(IL-33), matrix metalloproteinase-1(TIMP-1), and matrix metalloproteinase-2(MMP-2) in patients with chronic hepatitis B cirrhosis (HBC).The relationship between IL-33, TIMP-1, and MMP-2 levels and different degrees of cirrhosis and their prognostic value were analyzed.  Methods  From January 2021 to December 2022, 60 patients with HBC compensation (compensation group), 60 patients with HBC decompensation (decompensation group), and 60 patients with chronic hepatitis B without liver cirrhosis (chronic group) were selected.To analyze the relationship between serum levels of IL-33, TIMP-1, and MMP-2 and the occurrence of cirrhosis.The value of serum IL-33, TIMP-1, and MMP-2 on the prognosis of patients with chronic hepatitis B cirrhosis was evaluated by the ROC curve.  Results  The serum levels of IL-33, TIMP-1, and MMP-2 in the decompensated group were higher than those in the compensated and chronic groups (P < 0.05).The levels of IL-33, TIMP-1, and MMP-2 in the compensated group were higher than those in the chronic group (P < 0.05).Serum levels of IL-33, TIMP-1, and MMP-2 in 180 patients with chronic hepatitis B were positively correlated with cirrhosis (r=0.784, 0.691, 0.698, all P < 0.001).ROC results showed that the sensitivity of serum IL-33, TIMP-1, and MMP-2 levels to detect poor prognosis in patients with chronic hepatitis B cirrhosis were 81.25%, 81.25%, and 84.37%, and the specificity were 69.32%, 68.18%, and 71.59%, respectively.The AUC were 0.762, 0.734, and 0.830, respectively.  Conclusion  Serum IL-33, TIMP-1, and MMP-2 are highly expressed in patients with chronic hepatitis B cirrhosis, and they are positively correlated with the occurrence of cirrhosis.Especially, serum MMP-2 has a higher predictive value for poor prognosis in patients.

     

    • FullText(HTML)
  • loading
    • References(20)
  • [1]
    徐晨, 宋晓玲, 王洪林. 慢性乙型肝炎患者免疫-炎症因子与肝组织病理的相关性研究[J]. 中国临床医生杂志, 2020, 48(12): 1449-1452.

    XU C, SONG X L, et al. Study on the correlation between immune-inflammatory factors and liver histopathology in patients with chronic hepatitis B[J]. Chin J Clinician, 2020, 48(12): 1449-1452.
    [2]
    潘丽雅, 宋侨伟. 基于CT的全肝影像组学模型评价乙型肝炎肝纤维化分期的价值[J]. 浙江临床医学, 2023, 25(7): 975-977.

    PAN L Y, SONG Q W. Evaluation of liver fibrosis stage of hepatitis B by whole liver imaging model based on CT[J]. J Zhejiang Clin Med, 2023, 25(7): 975-977.
    [3]
    YANG M, WEI L. Impact of NAFLD on the outcome of patients with chronic hepatitis B in asia[J]. Liver Int, 2022, 42(9): 1981-1990.
    [4]
    ZHOU E, YANG C, GAO Y. Effect of alcohol on the progress of hepatitis B cirrhosis[J]. Ann Palliat Med, 2021, 10(1): 415-424.
    [5]
    WU J, CHEN Y, ZUO C, et al. A novel index for staging hepatitis B related liver cirrhosis in patients with hepatocellular carcinoma[J]. Sci Prog, 2021, 104(2): 368504211018052. DOI: 10.1177/00368504211018052.
    [6]
    BASKIRAN A, ATAYT A, BASKIRAN D Y, et al. Hepatitis B/D-related hepatocellular carcinoma. A clinical literature review[J]. J Gastrointest Cancer, 2021, 52(4): 1192-1197.
    [7]
    GINōS P, CASTERA L, LAMMERT F, et al. Population screening for liver fibrosis: toward early diagnosis and intervention for chronic liver diseases[J]. Hepatology, 2022, 75(1): 219-228.
    [8]
    中华医学会肝病学分会. 肝硬化诊治指南[J]. 中华肝脏病杂志, 2019, 27(11): 846-865.

    Hepatology Branch of Chinese Medical Association. Guidelines for Diagnosis and Treatment of cirrhosis[J]. Chin J Hepatology, 2019, 27(11): 846-865.
    [9]
    尤红, 王福生, 李太生, 等. 慢性乙型肝炎防治指南(2022年版)[J]. 实用肝脏病杂志, 2023, 26(3): 457-478.

    YOU H, WANG F S, LI T S. et al. Guidelines for the prevention and treatment of chronic hepatitis B (2022 edition)[J]. J Practical Hepatology, 2023, 26(3): 457-478.
    [10]
    RODRIGUEZ-TAJES S, PPCURULL A, LENS S, et al. Efficacy of an accelerated double-dose hepatitis B vaccine regimen in patients with cirrhosis[J]. J Viral Hepat, 2021, 28(7): 1019-1024. doi: 10.1111/jvh.13509
    [11]
    CAI F, ZHAO Y, CHEN Q, et al. Serum cytokine analysis reveals predictors of progression from chronic hepatitis B to liver cirrhosis[J]. Folia Biol(Praha), 2021, 67(1): 28-36.
    [12]
    GAO Z, SHEN Z, WU J, et al. Interleukin-33 mediates both immune-related and non-immune-related inhibitory effects against hepatitis B virus[J]. Antiviral Res, 2022, 206: 105404. DOI: 10.1016/j.antiviral.2022.105404.
    [13]
    袁媛, 陈洁, 杨雪梅, 等. 复方甘草酸苷治疗乙型肝炎肝硬化的疗效及对血清IL-17、IL-6、TGF-β和MMP-2水平的影响[J]. 临床与病理杂志, 2020, 40(8): 2085-2091.

    YUAN Y, CHEN J, YANG X M, et al. Effect of compound glycyrrhizin in the treatment of Hepatitis B cirrhosis and its effect on serum levels of IL-17, IL-6, TGF-β and MMP-2[J]. Chin J Clinl Pathology, 2020, 40(8): 2085-2091.
    [14]
    郭瑞雪, 魏新亮, 魏思忱. 慢性乙型肝炎患者血清脂联素、基质金属蛋白酶-2与肝纤维化的关系研究[J]. 检验医学与临床, 2020, 17(12): 1666-1668.

    GUO R X, WEI X L, WEI S C. Study on the relationship between serum adiponectin, matrix metalloproteinase-2 and liver fibrosis in patients with chronic hepatitis B[J]. Laboratory Medicine and Clinic, 2020, 17(12): 1666-1668.
    [15]
    张意钗, 罗胜强, 岑美婷. IL-33、TIMP-1、MMP-2联合乙肝五项指标诊断慢性HBV肝纤维化的应用价值[J]. 临床和实验医学杂志, 2022, 21(13): 1387-1390.

    ZHANG Y C, LUO S Q, CEN M T. Application value of IL-33, TIMP-1, MMP-2 combined with five indexes of hepatitis B in the diagnosis of chronic HBV liver fibrosis[J]. J Clin Exp Med, 2022, 21(13): 1387-1390.
    [16]
    曹海丹, 罗晓蓉, 吴县斌. 肝纤维化指标、TIMP-1在慢性乙型肝炎纤维化中的诊断效能及与肝硬化的关联性分析[J]. 重庆医学, 2021, 50(6): 991-995.

    CAO H D, LUO X R, WU X B. Index of liver fibrosis, diagnostic efficacy of TIMP-1 in chronic hepatitis B fibrosis and its association with cirrhosis[J]. Chongqing Medicine, 2021, 50(6): 991-995.
    [17]
    LIAO M J, LI J, DANG W, et al. Novel index for the prediction of significant liver fibrosis and cirrhosis in chronic hepatitis B patients in China[J]. World J Gastroenterol, 2022, 28(27): 3503-3513.
    [18]
    WANG X, WEI S, WEI Y, et al. The impact of concomitant metabolic dysfunction-associated fatty liver disease on adverse outcomes in patients with hepatitis B cirrhosis: a propensity score matching study[J]. Eur J Gastroenterol Hepatol, 2023, 35(8): 889-898.
    [19]
    刘文艳, 马世河, 黄贵, 等. 恩替卡韦治疗的乙型肝炎肝硬化患者血清TIMP-1、MMP-2和GP73水平变化[J]. 肝脏, 2022, 27(5): 536-539.

    LIU W Y, MA S H, HUANG G, et al. Changes of serum TIMP-1, MMP-2 and GP73 levels in patients with hepatitis B cirrhosis treated with entecavir[J]. Liver, 2022, 27(5): 536-539.
    [20]
    杨建波, 张欢, 马欢, 等. 乙肝肝硬化与慢性乙肝患者生化指标的比较[J]. 中国热带医学, 2022, 22(2): 129-133.

    YANG J B, ZHANG H, MA H, et al. Comparison of biochemical indexes in patients with hepatitis B cirrhosis and chronic hepatitis B[J]. China Tropical Medicine, 2022, 22(2): 129-133.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (10) PDF downloads(1) Cited by()
    Proportional views
    Related

    Address：No. 287, Changhuai Road, Bengbu, Anhui Province, 233004, P.R.ChinaphoneNo：0552-3066635； 0552-3051890Email：zhqkyx@163.com

    Copyright © Chinese Journal of General Practice皖ICP备2020018345号-2

    Supported by: Beijing Renhe Information Technology Co., Ltd.    

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return